HIV Drug / Medicine Market 2017
HIV Drug market is one of the growing drug markets across the globe. There has been a significant rise in number of HIV population worldwide. On the other hand, increase in number of cases of infection transmission through contaminated needles or infected blood has been registered in last few years. Breast milk, unprotected sex is the most common & big route of HIV to infect a large number of population across the globe and decrease the immunity of protection against infections.
Several government initiatives have been started and awareness programs are entertained in order to minimize the burden of HIV across the globe. Improvements in medicinal therapies like antiretroviral therapy (ART) which are also affordable for the patients suffering from HIV helps in the overall care and also increasing life expectancy of the patients. In 2014, 25 antivirals, 16 vaccines and 3 gene therapies have been introduced in the U.S. to improve treatment facilities with better and effective cure. Several drugs have been recently licensed for the treatment of HIV-1 infected patients. These new drugs include CCR5 co-receptor antagonist which is using for the patients those have developed resistance from previous drugs and therapies.
Market size and forecast
The HIV Drug market is expected to expand at a CAGR of 5.93% during the forecast period 2015-2023. The HIV Drug market is expected to reach USD 38.01 Billion by 2023 from USD 26.9 Billion in 2015.
The U.S. is expected to showcase a lucrative growth in HIV Drug market in the forecast period and HIV Drug market is expected to reach USD 2.2 Billion during the forecast period i.e. 2015-2023 in the region. HIV Drug market is expected to expand at a rapid pace over the forecast period 2015-2023 due to introduction of new and effective drugs with less side-effect which will spur the demand for HIV drugs across the globe.
Global HIV Drug Market is further segmented on the basis of drugs type as follows:
Demand Analysis By Original Drugs
Demand Analysis By Generic Drugs
Demand Analysis By Drugs Type
- Multi class combination products
- Nucleoside reverse transcriptase inhibitors
- Non-nucleoside reverse transcriptase inhibitors
- Entry inhibitors – CCR5 co-receptor antagonist
- Fusion inhibitors
- Protease inhibitors
- HIV integrase strand transfer inhibitors
HIV Drug Market is further classified on the basis of region as follows:
- North America (United States / U.S., Canada) Market Size and Y-O-Y Growth Analysis
- Latin America (Mexico, Brazil, Rest of Latin America) Market Size and Y-O-Y Growth Analysis
- Western and Eastern Europe (Germany, Italy, Spain, France, U.K, Benelux, Hungary, Rest Of Western Europe, Russia Poland, Rest of Eastern Europe) Market Size and Y-O-Y Growth Analysis
- Asia-Pacific (China, India, Singapore, Japan, Australia and New Zealand and Rest of Asia) Market Size and Y-O-Y Growth Analysis
- Middle East and North Africa (MENA) Market Size and Y-O-Y Growth Analysis
Growth Drivers and challenges
Lack of awareness in under developed nations towards protected sex is likely to further raise the population suffering from HIV which is further believed to increase the growth of HIV drug market across the globe during the forecast period 2015-2023. Advancement in healthcare and drug technology due to huge funding in Research and Development sector would help the companies to develop more effective drugs to restrict the dysfunctions and loss of immunity in the human body and is expected to grow the demand of HIV drug and further enforce the market of HIV drug globally.Further, governmental initiatives and rising awareness towards HIV and its carrier is anticipated to propel the demand for HIV drug market over the forecast period 2015-2023 globally. Apart from this, huge funding from the governmental authorities to provide better facilities and cure at affordable cost will make buyers to adopt the precautions related to HIV which is expected to propel further expand the demand of HIV drug market globally. Availability of Anti-retroviral Therapy (ART) with efficient fixed-dose combination reduces the burden of taking excess of pills to keep the infection inactive on the human body which helps the patients to opt these therapies with minimized number of dose. These therapies are expected to grow the demand of HIV Drug over the forecast period i.e. 2015-2023.
The key developers of HIV Drugs across the globe as follows:
- Company Overview
- Key Product Offerings
- Business Strategy
- SWOT Analysis
- Johnson and Johnson
- Hetero Drugs
- Gilead Sciences
Scope and Context
Overview of the Parent Market
The Global HIV Drug market is segmented as follows:
- By Original Drugs Market Size and Y-O-Y Growth Analysis
- By Generic Drugs Market Size and Y-O-Y Growth Analysis
- By Drugs Type Market Size and Y-O-Y Growth Analysis
Supply and Demand Risk
Porter’s Five Force Model
Geographical Economic Activity
Key Players (respective SWOT Analysis) and their Strategies and Product Portfolio
Recent Trends and Developments
Recent News and Developments
September 15, 2016: High court of England ruled to health department of the respective nation to provide appropriate measures to cure HIV infected people and arrange services to prevent the spread of HIV by providing anti-retroviral drug to the affected patients.
September 20, 2016: Scientists of U.S. and Canada developed a new innovative way to find the hidden infected cells. This new research opens up new doors to provide better treatment for HIV infected people across the globe.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)